Christine B. Mackay
Research Subjects
Christine B. Mackay has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Shellie D. Ellis
University of Kansas School of Medicine, Kansas City, KS
3 shared publications - Kirsten D. Erickson
Univeristy of Kansas Cancer Center, Fairway, KS
2 shared publications Prabhakar Chalise
University of Kansas Medical Center, Department of Biostatistics, USA
2 shared publications- Takefumi Komiya
Division of Hematology Oncology, Penn State College of Medicine, Hershey, USA
2 shared publications - Andrew Zganjar
Department of Urology, Mayo Clinic, Rochester, MN
1 shared publication - Ariel Shifter
Department of Population Health, University of Kansas School of Medicine, 3901 Rainbow Blvd., MS 3044, Kansas City, KS, 66160, USA
1 shared publication
Latest Publications
- Open Access
- 7 October 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-13
Development, acceptability, appropriateness and appeal of a cancer clinical trials implementation intervention for rural- and minority-serving urology practices
Background: Few community urologists offer cancer patients the opportunity to participate in cancer clinical trials, despite national guidelines that recommend it, depriving an estimated 260,000 urological cancer patients of guideline-concordant care each year. Existing strategies to increase urologists’ offer of clinical trials are designed for resource-rich environments and are not feasible for many community urologists. We sought to design an implementation intervention for dissemination in under-resourced community urology practices and to compare its acceptability, appropriateness and adoption appeal among trial-naïve and trial-experienced urologists.Methods: We used a design-for-dissemination approach, informed by the Theoretical Domains Framework and Behavior Change Wheel, to match determinants of the clinical trial offer to theoretically informed implementation strategies. We described the implementation intervention in evaluation workshops offered at urology professional society meetings. We surveyed participants to assess the implementation intervention’s acceptability and appropriateness using validated instruments. We also measured adoption appeal, intention to adopt and previous trial offer.Results: Our design process resulted in a multi-modal implementation intervention, comprised of multiple implementation strategies designed to address six domains from the Theoretical Domains Framework. Evaluation workshops delivered at four meetings, convened five separate professional societies. Sixty-one percent of those offered an opportunity to participate in the implementation intervention indicated intention to adopt. Average implementation intervention acceptability and appropriateness ratings were 4.4 and 4.4 (out of 5), respectively. Acceptability scores were statistically significantly higher among those offering trials compared to those not (p = 0.03). Appropriateness scores did not differ between those offering trials and those not (p = 0.24). After urologists ranked their top three innovation attributes, 43% of urologists included practice reputation in their top three reasons for offering clinical trials; 30% listed practice differentiation among their top three reasons. No statistically significant differences were found between those who offered trials and those who did not among any of the innovation attributes.Conclusions: LEARN|INFORM|RECRUIT is a promising implementation intervention to address low accrual to clinical trials, poised for implementation and effectiveness testing. The implementation intervention is appealing to its target audience and may have equal uptake among trial-naïve and trial-experienced practices.
- 7 October 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-13
Open AccessDevelopment, acceptability, appropriateness and appeal of a cancer clinical trials implementation intervention for rural- and minority-serving urology practices
Background: Few community urologists offer cancer patients the opportunity to participate in cancer clinical trials, despite national guidelines that recommend it, depriving an estimated 260,000 urological cancer patients of guideline-concordant care each year. Existing strategies to increase urologists’ offer of clinical trials are designed for resource-rich environments and are not feasible for many community urologists. We sought to design an implementation intervention for dissemination in under-resourced community urology practices and to compare its acceptability, appropriateness and adoption appeal among trial-naïve and trial-experienced urologists.Methods: We used a design-for-dissemination approach, informed by the Theoretical Domains Framework and Behavior Change Wheel, to match determinants of the clinical trial offer to theoretically informed implementation strategies. We described the implementation intervention in evaluation workshops offered at urology professional society meetings. We surveyed participants to assess the implementation intervention’s acceptability and appropriateness using validated instruments. We also measured adoption appeal, intention to adopt and previous trial offer.Results: Our design process resulted in a multi-modal implementation intervention, comprised of multiple implementation strategies designed to address six domains from the Theoretical Domains Framework. Evaluation workshops delivered at four meetings, convened five separate professional societies. Sixty-one percent of those offered an opportunity to participate in the implementation intervention indicated intention to adopt. Average implementation intervention acceptability and appropriateness ratings were 4.4 and 4.4 (out of 5), respectively. Acceptability scores were statistically significantly higher among those offering trials compared to those not (p = 0.03). Appropriateness scores did not differ between those offering trials and those not (p = 0.24). After urologists ranked their top three innovation attributes, 43% of urologists included practice reputation in their top three reasons for offering clinical trials; 30% listed practice differentiation among their top three reasons. No statistically significant differences were found between those who offered trials and those who did not among any of the innovation attributes.Conclusions: LEARN|INFORM|RECRUIT is a promising implementation intervention to address low accrual to clinical trials, poised for implementation and effectiveness testing. The implementation intervention is appealing to its target audience and may have equal uptake among trial-naïve and trial-experienced practices.
- 1 September 2017
- Published by Elsevier in Respiratory Investigation
- Vol. 55 (5) , 308-313
Who treats lung cancer? Results from a global survey
- 1 September 2017
- Published by Elsevier in Respiratory Investigation
- Vol. 55 (5) , 308-313
Who treats lung cancer? Results from a global survey
Insurance denials for cancer clinical trial participation after the Affordable Care Act mandate
BACKGROUND: The Affordable Care Act (ACA) includes a mandate requiring most private health insurers to cover routine patient care costs for cancer clinical trial participation; however, the impact of this provision on cancer centers’ efforts to accrue patients to clinical trials has not been well described.METHODS: First, members of cancer research centers and community‐based institutions (n = 252) were surveyed to assess the status of insurance denials, and then, a focused survey (n = 77) collected denial details. Univariate and multivariate analyses were used to examine associations between the receipt of denials and site characteristics.RESULTS: Overall, 62.7% of the initial survey respondents reported at least 1 insurance denial during 2014. Sites using a precertification process were 3.04 times more likely to experience denials (95% confidence interval, 1.55‐5.99; P ≤ .001), and similar rates of denials were reported from sites located in states with preexisting clinical trial coverage laws versus states without them (82.3% vs 85.1%; χ = 50.7; P ≤ .001). Among the focused survey sites, academic centers reported denials more often than community sites (71.4% vs 46.4%). The failure of plans to cover trial participation was cited as the most common reason provided for denials (n = 33 [80.5%]), with nearly 80% of sites (n = 61) not receiving a coverage response from the insurer within 72 hours.CONCLUSIONS: Despite the ACA's mandate for most insurers to cover routine care costs for cancer clinical trial participation, denials and delays continue. Denials may continue because some insurers remain exempt from the law, or they may signal an implementation failure. Delays in coverage may affect patient participation in trials. Additional efforts to eliminate this barrier will be needed to achieve federal initiatives to double the pace of cancer research over the next 5 years. Future work should assess the law's effectiveness at the patient level to inform these efforts. Cancer 2017;123:2893–900. © 2017 American Cancer Society.
Insurance denials for cancer clinical trial participation after the Affordable Care Act mandate
BACKGROUND: The Affordable Care Act (ACA) includes a mandate requiring most private health insurers to cover routine patient care costs for cancer clinical trial participation; however, the impact of this provision on cancer centers’ efforts to accrue patients to clinical trials has not been well described.METHODS: First, members of cancer research centers and community‐based institutions (n = 252) were surveyed to assess the status of insurance denials, and then, a focused survey (n = 77) collected denial details. Univariate and multivariate analyses were used to examine associations between the receipt of denials and site characteristics.RESULTS: Overall, 62.7% of the initial survey respondents reported at least 1 insurance denial during 2014. Sites using a precertification process were 3.04 times more likely to experience denials (95% confidence interval, 1.55‐5.99; P ≤ .001), and similar rates of denials were reported from sites located in states with preexisting clinical trial coverage laws versus states without them (82.3% vs 85.1%; χ = 50.7; P ≤ .001). Among the focused survey sites, academic centers reported denials more often than community sites (71.4% vs 46.4%). The failure of plans to cover trial participation was cited as the most common reason provided for denials (n = 33 [80.5%]), with nearly 80% of sites (n = 61) not receiving a coverage response from the insurer within 72 hours.CONCLUSIONS: Despite the ACA's mandate for most insurers to cover routine care costs for cancer clinical trial participation, denials and delays continue. Denials may continue because some insurers remain exempt from the law, or they may signal an implementation failure. Delays in coverage may affect patient participation in trials. Additional efforts to eliminate this barrier will be needed to achieve federal initiatives to double the pace of cancer research over the next 5 years. Future work should assess the law's effectiveness at the patient level to inform these efforts. Cancer 2017;123:2893–900. © 2017 American Cancer Society.
- 27 October 2016
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 22 (2) , 237-243
Status of oncologic specialties: global survey of physicians treating cancer
In the United States, medical oncologists play a central role in the management of systemic therapy for cancer patients. Medical oncology as a specialty is not as established in Japan and several other European nations according to recent surveys, and little is known about this specialty in developing nations. We aimed to identify global differences in the roles of physicians treating cancer; specifically, how the management of advanced disease differs among nations. In March 2016, a self-administered internet survey was conducted with degreed physicians who prescribed systemic agents for adult cancer treatment within the past 5 years. Physicians were identified from the American Society of Clinical Oncology active member online directory. Among 3907 members in 55 nations, 376 (9.6%) responded to the survey. The 310 respondents who provided an answer to the recognition of medical oncology were dominated by male MDs that have practiced for more than 5 years at academic centers, and ~60% were medical oncologists. A majority of the respondents in all four regions reported that medical oncology was established in their corresponding nations. However, there are several outlying nations where oncologic specialties play a minimal role in the management of systemic therapy. Despite general recognition of medical oncology, the role is not globally established as the primary point of care for delivery of systemic therapy. Nations lacking this specialty should be assisted by the international community to develop medical oncology.
- 27 October 2016
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 22 (2) , 237-243
Status of oncologic specialties: global survey of physicians treating cancer
In the United States, medical oncologists play a central role in the management of systemic therapy for cancer patients. Medical oncology as a specialty is not as established in Japan and several other European nations according to recent surveys, and little is known about this specialty in developing nations. We aimed to identify global differences in the roles of physicians treating cancer; specifically, how the management of advanced disease differs among nations. In March 2016, a self-administered internet survey was conducted with degreed physicians who prescribed systemic agents for adult cancer treatment within the past 5 years. Physicians were identified from the American Society of Clinical Oncology active member online directory. Among 3907 members in 55 nations, 376 (9.6%) responded to the survey. The 310 respondents who provided an answer to the recognition of medical oncology were dominated by male MDs that have practiced for more than 5 years at academic centers, and ~60% were medical oncologists. A majority of the respondents in all four regions reported that medical oncology was established in their corresponding nations. However, there are several outlying nations where oncologic specialties play a minimal role in the management of systemic therapy. Despite general recognition of medical oncology, the role is not globally established as the primary point of care for delivery of systemic therapy. Nations lacking this specialty should be assisted by the international community to develop medical oncology.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18174
Identifying patients for clinical trials: Evaluation of NCI-designated community cancer centers.
E18174 Background: The University of Kansas Cancer Center achieved NCI designation in 2012, and the year prior, acquired 5 outpatient cancer clinics, which contributed to nearly a doubling of the tumor registry cases. Prior to this merger, these practices were part of one of the nation’s largest site management organization networks of community-based oncology practices and were consistently listed as top accruing sites for many of the trials that were conducted. Soon after the merger, clinical trial enrollment dropped significantly, providing a unique opportunity to analyze the reasons for this drastic change in accrual patterns. The primary aim of this study was to identify what factors influence how patients are identified for possible clinical trial participation. Methods: This was a cross-sectional qualitative design. Individual interviews were conducted with 27 physicians and nurse practitioners. Six focus groups included 26 clinical and research staff. Descriptive summary statistics and standard text analysis were performed to summarize responses. Results: The top three factors reported to affect patient identification included: 1) absence of research staff in the clinic, 2) low physician engagement in the clinical trial process, and 3) a general lack of awareness of clinical trials by providers, clinic and research staff. 100% of the providers interviewed agreed that clinical trials are beneficial for patients as well as the practice, and most (98%) agreed the physician is primarily responsible for patient identification. Conclusions: The results from this project support the literature which suggests that physicians are the most significant factor in successful recruitment of patients to cancer clinical trials but adequate organizational support is necessary. Centers considering expanding their network to include community locations should be aware of how organizational changes may affect physician ability to accrue.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18174
Identifying patients for clinical trials: Evaluation of NCI-designated community cancer centers.
E18174 Background: The University of Kansas Cancer Center achieved NCI designation in 2012, and the year prior, acquired 5 outpatient cancer clinics, which contributed to nearly a doubling of the tumor registry cases. Prior to this merger, these practices were part of one of the nation’s largest site management organization networks of community-based oncology practices and were consistently listed as top accruing sites for many of the trials that were conducted. Soon after the merger, clinical trial enrollment dropped significantly, providing a unique opportunity to analyze the reasons for this drastic change in accrual patterns. The primary aim of this study was to identify what factors influence how patients are identified for possible clinical trial participation. Methods: This was a cross-sectional qualitative design. Individual interviews were conducted with 27 physicians and nurse practitioners. Six focus groups included 26 clinical and research staff. Descriptive summary statistics and standard text analysis were performed to summarize responses. Results: The top three factors reported to affect patient identification included: 1) absence of research staff in the clinic, 2) low physician engagement in the clinical trial process, and 3) a general lack of awareness of clinical trials by providers, clinic and research staff. 100% of the providers interviewed agreed that clinical trials are beneficial for patients as well as the practice, and most (98%) agreed the physician is primarily responsible for patient identification. Conclusions: The results from this project support the literature which suggests that physicians are the most significant factor in successful recruitment of patients to cancer clinical trials but adequate organizational support is necessary. Centers considering expanding their network to include community locations should be aware of how organizational changes may affect physician ability to accrue.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e14047
Predictors of insurance denials for cancer clinical trial participation after ACA mandate.
E14047 Background: A recent federal initiative, the Cancer Moonshot, to develop and complete randomized clinical trials in four years for tens of thousands of US cancer patients may face a hurdle. As of January 1, 2014, the ACA requires most health insurers to cover routine patient care costs when receiving treatment through a clinical trial, however the effects of this law have not been reported. Most states had laws or agreements for clinical trial coverage in place prior to the enactment of the ACA, but previous literature reported variable outcomes from these regulations, possibly due to inadequate enforcement. We aimed to evaluate the implementation of the ACA clinical trial mandate, specifically to determine if insurance denials persist and what cancer center characteristics are associated with reporting denials. Methods: We conducted two complementary cross-sectional surveys of members of cancer organizations representing leading cancer research centers and community based institutions which conduct treatment clinical trials. Results: Of the evaluable responses (252) from the initial survey representing the District of Columbia and all but 2 states, more than half of cancer centers (62.7%) reported having received at least one insurance denial during 2014, and those sites using a precertification process were 3 times more likely (95% CI, 1.55-5.99) to experience denials. Of the detailed survey respondents (n = 66), both academic (76.5%) and community (46.9%) sites reporting experiencing denials and most sites (86.4%) utilize a precertification process. The most common (80.6%) reason given for a denial from the insurer was plan not covering clinical trial participation. Academic center denials due to phase not covered and site out of network were statistically significant (p-values 0.011 and 0.001). Conclusions: Insurance denials for obtaining treatment through a clinical trial persist despite the ACA mandate. More academic than community centers experience this barrier. Further evaluation of ACA implementation is needed ensure adequate access to care and the ability to move the field forward.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e14047
Predictors of insurance denials for cancer clinical trial participation after ACA mandate.
E14047 Background: A recent federal initiative, the Cancer Moonshot, to develop and complete randomized clinical trials in four years for tens of thousands of US cancer patients may face a hurdle. As of January 1, 2014, the ACA requires most health insurers to cover routine patient care costs when receiving treatment through a clinical trial, however the effects of this law have not been reported. Most states had laws or agreements for clinical trial coverage in place prior to the enactment of the ACA, but previous literature reported variable outcomes from these regulations, possibly due to inadequate enforcement. We aimed to evaluate the implementation of the ACA clinical trial mandate, specifically to determine if insurance denials persist and what cancer center characteristics are associated with reporting denials. Methods: We conducted two complementary cross-sectional surveys of members of cancer organizations representing leading cancer research centers and community based institutions which conduct treatment clinical trials. Results: Of the evaluable responses (252) from the initial survey representing the District of Columbia and all but 2 states, more than half of cancer centers (62.7%) reported having received at least one insurance denial during 2014, and those sites using a precertification process were 3 times more likely (95% CI, 1.55-5.99) to experience denials. Of the detailed survey respondents (n = 66), both academic (76.5%) and community (46.9%) sites reporting experiencing denials and most sites (86.4%) utilize a precertification process. The most common (80.6%) reason given for a denial from the insurer was plan not covering clinical trial participation. Academic center denials due to phase not covered and site out of network were statistically significant (p-values 0.011 and 0.001). Conclusions: Insurance denials for obtaining treatment through a clinical trial persist despite the ACA mandate. More academic than community centers experience this barrier. Further evaluation of ACA implementation is needed ensure adequate access to care and the ability to move the field forward.
- Open Access
- 1 April 2016
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 2, 69-74
Clinical trial insurance coverage for cancer patients under the Affordable Care Act
- 1 April 2016
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 2, 69-74
Open AccessClinical trial insurance coverage for cancer patients under the Affordable Care Act